The early use of antibiotics for ‘at risk’ children with influenza
Double-blind randomised placebo-controlled trial whose primary objective is to determine whether treatment with a 5-day course of co-amoxiclav early during an influenza/ILI episode in at risk children reduces the likelihood of re-consultation due to clinical deterioration.
‘At risk’ children are defined as children with underlying medical conditions or risk factors associated with an increased likelihood of developing influenza/ILI-related complications. Influenza/ILI is well recognised as a predisposing factor for secondary complications, including bacterial infections, which may result in children consulting a clinician more than once during the same illness episode due to clinical deterioration. Influenza and influenza-like illness (ILI) in children create a considerable burden on NHS resources each winter.
An effective, evidence-based policy on antibiotic use in at risk children during influenza season is needed to ensure that national antibiotic stockpiles are used in the most clinically appropriate and cost-effective way. This trial will determine whether early treatment with the antibiotic co-amoxiclav reduces the likelihood of re-consultation due to clinical deterioration in at risk children who present with influenza/ILI in primary care.
|Study Design:||Double-blind randomised placebo-controlled trial|
|Sponsor:||University of Oxford|
|Chief Investigator:||Dr Kay Wang, University of Oxford|
|Ethical approval:||EudraCT Number: 2013-002822-21|